|
Author Archive: AZBio
Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals Inc., combination therapy offers the potential of a safer and more effective approach to a wide variety of cancer treatments
Oncology Pharma is pleased to announce that Kalos Therapeutics’ lead compound, KTH-222, can produce a reduction in the attachment of newly seeded cells to a solid-phase by an average of 39%. These non-clinical results suggest that KTH-222 disrupt tubulin formation and attachment to the solid-phase in a similar way to most of the commonly used tubulin disrupting chemotherapeutic drugs. However, the mechanism of action by KTH-222 may be different than the most commonly used tubulin-disrupting therapies and needs further investigation. Continue reading
Arizona State University’s Biodesign Institute C Research Building Receives LEED Platinum Certification
The $120 million Biodesign Institute C research building at Arizona State University (ASU), which was constructed by McCarthy Building Companies and completed in June 2018, recently received LEED Platinum certification from the U.S. Green Building Council.Continue reading
Discovery may expand cancer vaccine capabilities
For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University’s Biodesign Institute have pooled their energies into an often scoffed-at, high-risk, high-reward goal in medicine: to develop a universal vaccine to prevent cancer.Continue reading
Cereset® Announces Mild-Traumatic Brain Injury Focused Clinical Trial Progress
Results to date demonstrate that Cereset’s technology may help U.S. military personnel suffering from concussionContinue reading
First Annual University Flu Shot Challenge Launched at Several Arizona Campuses
New Campaign Brings Awareness About the Importance of Flu Vaccination to AZ StudentsContinue reading
PathogenDx Announces $7.5 Million in Series B Funding
DNA-based pathogen testing company completes funding round led by Cresco Capital Partners in just three monthsContinue reading
Is Life Science Innovation At Risk?
Opinion: Speaker Pelosi’s Drug Pricing Plan “Crushes the Desperate Hopes of Patients and their Families”
Click here to listen to an interview with BIO President and CEO, Jim Greenwood.
Onco ‘Zine Interview Highlights Arizona Life Science Innovators
Listen to the Onco’Zine Brief hosted by Peter Holfland: A Commitment to Innovation in Medicines, Medical Devices and Healthcare TechnologiesContinue reading